Reneuron Share Discussion Threads

[dickbush] 28/4/2016 09:48

Follow-up on BBC World Service at about 6.15 this morning.

More on

[dogwalker] 28/4/2016 08:20

It's a 'next year or the year after that' kind of company. Always has been.

[noteworthy5] 27/4/2016 21:46

And their cancer drug going into Phase 1 next year.

[noteworthy5] 27/4/2016 21:29

Phase 1 and Phase 2a data due this Quarter. If the Phase 2a is decent it could mean a product worth £billions.

[stewart_25] 27/4/2016 11:50

agreed horneblower - seems to be dipping for no reason and settling back around 3p for no reason...

[horneblower] 27/4/2016 11:47

It will be interesting if it closes above 3.5p.
Otherwise...same old.

[stewart_25] 27/4/2016 11:20

Interesting movements...

[richtea1701] 27/4/2016 11:18

Hopefully the latter. But bored of the former.

[small crow] 27/4/2016 11:10

Hmm. The usual gyrations or something more?

[noteworthy5] 15/4/2016 08:16

The Phase 1 stroke study secondary outcomes will give readout on efficacy, i.e. Barthel Index, Mental State Examination, Rankin Score, etc. Not long to wait for the Phase 1 and 2 stroke results.

Wonder how many now recruited into the retinosa pigmentosa trial.

[dickbush] 12/4/2016 16:29

First half 2016: Data expected from

Phase 1 trial of critical limb eschaemia treatment

and

Phase 2 trial of stroke treatment.

The former is woth almost nothing to us as it is simply testing that the treatment does no harm. The latter should be worth something to the share price. The only question is, will it be positive or negative?

[city chappy] 11/4/2016 11:40

ReNeuron Group plc Placing to Raise £68.4 million
10/07/2015 6:01am
UK Regulatory (RNS & others)

Highlights

-- GBP68.4 million (before expenses) of firm commitments to be raised through an oversubscribed Placing of 1,367,411,939 new ordinary shares at a price of 5p per share.

-- Placing proceeds to provide working capital for core cell-based therapeutic programmes and new exosome nanomedicine programme in oncology through to first half of 2019.

-- Placing provides funding for stroke and retinitis pigmentosa programmes through to market authorisation application based on existing clinical development plans.

-- Placing supported by major new and existing institutional investors.

-- Issue Price represents a 2.5 per cent premium to the closing mid-market price of an existing ordinary share of 4.88p on 9 July 2015, being the last business day prior to this announcement.

[city chappy] 11/4/2016 11:39

RF you need to do some research.

The retinitis pigmentosa treatment is on the FDA's "fast track" route.

[norbus] 11/4/2016 11:17

I would not go as far as RF but he makes many good points; Shenanegans are part of the company history; Like fingerprints theses hardly ever change. Rene is a long way from proof of efficacy of the drugs for their respective applications; Like IEH, Intelligent Energy, they are fighting on too many fronts; IEH came to market at £3.4o They are at 15 and unable to raise funds. For that reason, I commend RF not as a troll, but a man who is wary of the management; I made money because I had a substantial holding then ditched at >6.5p when I came across the top management Mike Hunt saw how much they were taking out, and got the vibes he talks about. I do hope they succeed especially the stroke side as that will help loads of families but investors must excercise caution

[rocket fuel] 11/4/2016 11:01

No grudges here at all, just a reality check for the new holders who obviously jumped on board without doing their research.

[horneblower] 11/4/2016 10:54

You seem to have a grudge, rocket. Why so spiteful?

[rocket fuel] 11/4/2016 10:52

Nothing doing here with regards to FDA approval for at least five years minimum, and cash left in bank will last 18 months maximum.

[noteworthy5] 11/4/2016 10:41

The point about their cash balance is they now have enough to see them through to marketing applications for the retinitis pigmentosa and stroke drugs and Phase I results for the cancer drug at which point they should be able to sell the company for several £billions.

[norbus] 10/4/2016 12:20

£95m market cap;

£75m cash
(£70m) burn over 4 years

Binary; now under water @3p unless the technology is a world beater then maybe ok; Odds on or Long shot?? It is a romantic share

[city chappy] 09/4/2016 00:55

They raised £68.4 million in the above Placing last August and the Interim results in December said they had cash, cash equivalents and bank deposits at 30/9/2015 of £72.28 million. On 11/1/2016 they were awarded a further £2.1 million grant from Innovate UK to help advance exosomes in cancer.

[city chappy] 09/4/2016 00:53

ReNeuron Group plc Placing to Raise £68.4 million
10/07/2015 6:01am
UK Regulatory (RNS & others)

Highlights

-- GBP68.4 million (before expenses) of firm commitments to be raised through an oversubscribed Placing of 1,367,411,939 new ordinary shares at a price of 5p per share.

-- Placing proceeds to provide working capital for core cell-based therapeutic programmes and new exosome nanomedicine programme in oncology through to first half of 2019.

-- Placing provides funding for stroke and retinitis pigmentosa programmes through to market authorisation application based on existing clinical development plans.

-- Placing supported by major new and existing institutional investors.

-- Issue Price represents a 2.5 per cent premium to the closing mid-market price of an existing ordinary share of 4.88p on 9 July 2015, being the last business day prior to this announcement.

[norbus] 08/4/2016 08:42

RF

I remember well the fraud after ER as Patron of Stroke Society put £200000 in the shares, crashing, being bought back and refloated.

MiKehunt seems to me to be a shifty accountant on the make, who milked enough salary with Sindon to retire. He still seems to be boss here , possibly Chris Evans shadow on the board. No was could you straighten a dog's bent backleg. This will end in tears, once off risk, it will be bought in. You can't go against the form.

I also made money here, and have no intentin to get back; I have a friend here with a lot . I hope he will get out on a high, Woodford bought at 2.5 and 5 and maybe just above water, but the lack of returns will make it hard to show a profit
He will be protected in taking it private

[rocket fuel] 08/4/2016 08:24

H1 loss = £4.4m
Estimated FY loss = £15.2m (you can bet your butt it will be £16+m)
The shortfall is £11m burnt in the last six months.
The cash burn escalated in the last 3 months. Rene currently burn more than £2m per month. Note the use of the word currently, as well as the fact that rene are currently in fiscal yr 2017 (burn rate now is currently £2.5m per month)